An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
Status:
Withdrawn
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Phase 0 Study of an alternative dosing interval of Brodalumab in patients with moderate to
severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical
response.